Diagnosis and treatment of myalgic encephalomyelitis/chronic fatigue syndrome

This systematic review summarizes research on methods of diagnosing myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and benefits and harms of multiple medical and nonmedical treatments. It identifies evidence gaps and limitations to inform future research.

Citation
This systematic review summarizes research on methods of diagnosing myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS) and benefits and harms of multiple medical and nonmedical treatments. It identifies evidence gaps and limitations to inform future research. Diagnosis and treatment of myalgic encephalomyelitis/chronic fatigue syndrome. Rockville: Agency for Healthcare Research and Quality (AHRQ). Evidence Report/Technology Assessment No. 219. 2014

Authors' conclusions
None of the current diagnostic methods have been adequately tested to identify patients with ME/CFS when diagnostic uncertainty exists. Rintatolimod improves exercise performance in some patients (low strength of evidence), while counseling therapies and GET vihave broader benefit but have not been adequately tested in more disabled populations (low to moderate strength of evidence). Other treatments and harms have been inadequately studied (insufficient evidence). More definitive studies are needed to fill the many research gaps in diagnosing and treating ME/CFS.

Final publication URL

Indexing Status
Subject indexing assigned by CRD

MeSH
Fatigue Syndrome, Chronics

Language Published
English

Country of organisation
United States

English summary
An English language summary is available.

Address for correspondence
AHRQ, Center for Outcomes and Evidence Technology Assessment Program, 540 Gaither Road, Rockville, MD 20850, USA Email: AHRQTAAP@ahrq.hhs.gov

AccessionNumber
32014001423

Date abstract record published
11/12/2014